Back to search results

LATTICE Radiotherapy vs. Standard Radiation for Metastatic Cancer

This study is comparing two types of radiation therapy for patients with metastatic cancer (cancer that has spread). It's testing LATTICE Radiotherapy against standard palliative radiation. The goal is to see which treatment is better at shrinking tumors. You might be able to join if you are at least 12 years old, have metastatic cancer, and your tumor is larger than 2.5 cm. The study aims to enroll 80 participants. The current status of the study is unclear.

Study design
This is an unblinded, randomized study, meaning you and your doctors will know which treatment you are receiving. It plans to enroll 80 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your tumor volume will be measured about 90 days (plus or minus 20 days) after radiation therapy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07594431

Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases.

Recruiting
PHASE2Ages 12+InterventionalTreatment
Stanford University
~80 participants
Updated 2026-09-09 on ClinicalTrials.gov
What's tested:LATTICE RadiotherapyStandard radiotherapy

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percent Tumor Volume Reduction Following Radiotherapy
Measured over 90 +/- 20 days following radiotherapy

Conditions

Metastases
Metastatic Cancer

Explore related trials

Metastatic Malignant Neoplasm

NCT07594431

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Stanford University

    Palo Alto, Californiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Michael Gensheimer, MD · PRINCIPAL_INVESTIGATOR · Stanford University

Who to contact

Jamie Wang
[email protected]
650-497-4354
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Histologically, cytologically, or radiographically confirmed diagnosis of metastatic cancer
One to two metastases in non-brain sites that are amenable to LATTICE radiotherapy: \>2.5 cm in short axis (dimension on axial imaging that is perpendicular to the longest dimension); bone metastasis can be included if the extraosseous component is \>2.5 cm in short axis
Age ≥12
ECOG Performance Status 0-2
For patients age 12-16, Lansky Play-Performance score 50-100
Negative serum or urine pregnancy test within 2 weeks prior to enrollment of people of childbearing potential
All patients and/or their parents or legal guardians must sign a written informed consent. For any child less than 18 years of age, assent must also be obtained in addition to parental or legal guardian consent.

Exclusion

Prior radiation therapy to the tumor to be treated
Active pregnancy
Diseases that place the patient at high risk of radiation complications including lupus, scleroderma, Li Fraumeni syndrome
The tumor to be treated is from a hematologic malignancy such as lymphoma or myeloma

What this trial measures

  • Percent Tumor Volume Reduction Following Radiotherapy90 +/- 20 days following radiotherapy

    Radiographic response defined as percent tumor volume reduction 90 +/- 20 days following radiotherapy